by Clinical Neuropsychologist Online | Monday, October 12, 2026 | Dementia
Abstract INTRODUCTION Self-reported sleep duration is associated with dementia-risk and vascular brain injury markers, including white matter hyperintensities (WMHs), yet how additional cerebrovascular pathology alters these relationships remains unclear. METHOD In a...
by Clinical Neuropsychologist Online | Monday, October 12, 2026 | Dementia
Abstract In the future, treatment of dementia will be personalized, targeted to contributing pathologies, rather than the clinical syndrome. Anti-amyloid drugs for Alzheimer’s disease are the first approved drugs; however, the impact of co‑pathology on the...
by Clinical Neuropsychologist Online | Monday, October 12, 2026 | Dementia
Abstract INTRODUCTION ATN-stratified cerebrospinal fluid (CSF) proteomic signals may partly reflect classifier tau immunoassays; reproducible non-tau signals and CSF–plasma differences remain unclear. METHODS We profiled CSF from 60 A+ Beijing patients with...
by Clinical Neuropsychologist Online | Sunday, October 11, 2026 | Dementia
Abstract INTRODUCTION ApoE ε4 is the strongest genetic risk factor for Alzheimer’s disease (AD). Emerging evidence suggests that ApoE4 increases AD risk by disrupting microglial metabolism and function. However, whether ApoE lipidation state contributes to...
by Clinical Neuropsychologist Online | Sunday, October 11, 2026 | Dementia
Abstract INTRODUCTION Diabetes is associated with elevated risk of Alzheimer’s disease and related dementias (ADRD). Disease management with pharmaceutical therapies may mitigate this increased risk, but access and use of diabetes therapies are limited,...
